Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease

Pharmacogenomics

Volumn 10, Issue 3, 2009, Pages 463-476

  Rudnicki, Michael ^a   Mayer, Gert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiotensin converting enzyme gene polymorphism; Angiotensin converting enzyme inhibitors; Cardiovascular disorders; Renal disease; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN;

ASIAN; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INTRON; KIDNEY DISEASE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SODIUM BALANCE; TISSUE LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CARRIER STATE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT;

EID: 65649108517     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.3.463     Document Type: Review

References (99)

1. Tigerstedt R, Bergman PG: Niere und kreislauf. Skand. Arch. Physiol. 8, 223-271 (1898).
2. Goldblatt H, Lynch J, Hanzal RF, Summerville WW: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J. Exp. Med. 59, 347-379 (1934).
3. Pickering GW, Prinzmetal M: Some observations on renin, a pressor substance contained in normal kidney, together with a method for its biological assay. Clin. Sei. 3, 211-227 (1938).
4. Page IH, Helmer OM: A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J. Exp. Med. 71, 29-42 (1940).
5. Braun-Menendez E, Fasciolo JC, Leloir LF, Munoz JM: The substance causing renal hypertension. J. Physiol. 98(3), 283-298 (1940).
6. Elliott DF, Peart WS: Amino-acid sequence in a hypertensin. Nature 177(4507), 527-528 (1956).
7. Goodfriend TL, Lin SY: Receptors for angiotensin I and II. Circ. Res. 27(1 Suppl. 1), 163-174 (1970).
8. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP: The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J. Exp. Med. 106(3), 439-453 (1957).
9. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 45(2), 403-410 (1994).
10. Williams B: Angiotensin II and the pathophysiology of cardiovascular remodeling. Am. J. Cardiol. 87(8A), C10-C17 (2001).
11. Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196, 441-444 (1977).
12. Brenner BM, Cooper ME, de Zeeuw D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (12), 861-869 (2001).
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329(20), 1456-1462 (1993).
14. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349(9069), 1857-1863 (1997).
15. Aranda P, Segura J, Ruilope LM et al.: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am. J. Kidney Dis. 46(6), 1074-1079 (2005).
16. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchetti A: ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 13 (11), 1325-1334 (1995).
17. Wachtell K, Palmieri V, Olsen MH et al.: Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 106(2), 227-232 (2002).
18. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N. Engl. J. Med. 319(2), 80-86 (1988).
19. Pfeffer MA, McMurray JJ, Velazquez EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349(20), 1893-1906 (2003).
20. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N. Engl. J. Med. 327(10), 685-691 (1992).
21. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann. Intern. Med. 141(9), 693-704 (2004).
22. Madrid AH, Bueno MG, Rebollo JM et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106(3), 331-336 (2002).
23. Vermes E, Tardif JC, Bourassa MG et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23), 2926-2931 (2003).
24. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaernic attack. Lancet 358 (9287), 1033-1041 (2001).
25. Schrader J, Luders S, Kulschewgki A et al.: Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36(6), 12i8-1226 (2005).
26. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy, Lancet 352(9136), 1252-1256 (1998).
27. Materson BJ, Reda DJ, Cushman WC et al.: Single-drug therapy for hypertension in men, A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328(13), 914-921 (1993).
28. Heeg JE, de Jong PE, van der Hem GY, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 36(2), 272-279 (1989).
29. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
30. Danser AH, Schalekamp MA, Bax WA et al.: Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92(6), 1387-1388 (1995).
31. Rudnicki M, Mayer G: Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease - pathophysiological considerations. Pharmacogenomics 4(2), 153-162 (2003).
32. Weekers L, Bouhanick B, Hadjadj S et al.: Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric Type 1 diabetic patients. Diabetes 54(10), 2961-2967 (2005).
33. Ng DP, Tai BC, Koh D, Tan KW, Chia KS: Angiotensin-I converting enzyme insertion/deletion polvmorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48(5), 1008-1016 (2005).
34. Hadjadj S, Tarnow L, Forsblom C et al.: Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J. Am. Soc. Nephrol. 18(4), 1284-1291 (2007).
35. Wang Y, Ng MC, So WY et al.: Prognostic effect of insertion/ deletion polymorphism of the ACE gene on renal and cardiovascular clinical outcomes in Chinese patients with Type 2 diabetes. Diabetes Care 28(2), 348-354 (2005).
36. Hadjadj S, Fumeron F, Roussel R et al.: Prognostic value of the insertion/deletion polymorphism of the ACE gene in Type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de Type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 31(9), 1847-1852 (2008).
37. Pereira TV, Nunes AC, Rudnicki M et al.: Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. Nephrol. Dial. Transplant. 21(11), 3155-3163 (2006).
38. Yong D, Qing WQ, Hua L et al.: Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism and IgA nephropathy: a meta-analysis. Am. J. Nephrol. 26(5), 511-518 (2006).
39. Ruggenenti P, Perna A, Zoccali C et al.: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J. Am. Soc. Nephrol. 11(1), 88-96 (2000).
40. Samuelsson O, Attman PO, Larsson R et al.: Angiotensin I-converting enzyme gene polymorphism in non-diabetic renal disease. Nepbrol. Dial. Transplant. 15(4), 481-486 (2000).
41. Zee RY, Lou YK, Griffiths LR, Morris BJ: Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem. Biophys. Res. Commun. 184(1), 9-15 (1992).
42. Morris BJ, Zee RY, Schrader AP: Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals. J. Clin. Invest. 94(3), 1085-1089 (1994).
43. Harrap SB, Davidson HR, Connor JM et al.: The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 21(4), 455-460 (1993).
44. Staessen JA, Wang JG, Ginocchio G et al.: The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J. Hypertens. 15(12 Pt 2), 1579-1592 (1997).
45. Kuznetsova T, Staessen JA, Wang JG et al.: Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. J. Hum. Hypertens. 14(7), 447-454 (2000).
46. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116(2), 288-296 (2006).
47. Eijkelkamp WB, Zhang Z, Remuzzi G et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with Type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nepbrol. 18(5), 1540-1546 (2007).
48. Sarafidis PA, Khosla N, Bakris GL: Antihypertensive therapy in the presence of proteinuria. Am. J. Kidney Dis. 49 (1), 12-26 (2007).
49. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G: Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin. J. Am. Soc. Nephrol.(2008).
50. Ha SK, Yong Lee S, Su Park H et al.: ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect ofACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol. Dial. Transplant. 15(10), 1617-1623 (2000).
51. Yoshida H, Mitarai T, Kawamura T et al.: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J. Clin. Invest. 96(5), 2162-2169 (1995).
52. Gonzalo A, Telleria D, San Millan JL, Ortuno J: Angiotensin-converting enzyme gene polymorphism and antiproteinuric response to renoprotective therapy. Nephrol. Dial. Transplant. 13(4), 1050-1051 (1998).
53. Haas M, Yilmaz N, Schmidt A et al.: Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press. Res. 21(1), 66-69 (1998).
54. Jacobsen P, Rossing K, Rossing P et al.: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 53(4), 1002-1006 (1998).
55. Parving HH, Jacobsen P, Tarnow L et al.: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 313(7057), 591-594 (1996).
56. Penno G, Chaturvedi N, Talmud PJ et al.: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODI0AB Controlled Trial of Lisinopril in IDDM. Diabetes 47(9), 1507-1511 (1998).
57. Perna A, Ruggenenti P, Testa A et al.: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int. 57(1), 274-281 (2000).
58. van der Kleij FG, Navis GJ, Gansevoort RT et al.: ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol. Dial. Transplant. 12(Suppl. 2), 42-46 (1997).
59. van Essen GG, Rensma PL, de Zeeuw D et al.: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347(8994), 94-95 (1996).
60. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH: Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J. Am. Soc. Nephrol. 14(11), 2843-2850 (2003).
61. Moriyama T, Kitamura H, Ochi S et al.: Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J. Am. Soc. Nephrol. 6(6), 1676-1678 (1995).
62. So WY, Ma RC, Ozaki R et al.: Angiotensin-converting enzyme (ACE) inhibition in Type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism. Kidney Int. 69(8),1438-1443 (2006).
63. Bjorck S, Blohme G, Sylven C, Mulec H: Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol. Dial. Transplant. 12(Suppl. 2), 67-70 (1997).
64. Burg M, Menne J, Ostendorf T, Kliem V, Floege J: Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis. Clin. Nephrol. 48(4), 205-211 (1997).
65. van der Kleij FG, Schmidt A, Navis GJ et al.: Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int. Suppl. 63, S23-S26 (1997).
66. Luik PT, Hoogenberg K, Kerstens MN et al.: The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus. Diabetologia 46(8), 1131-1139 (2003).
67. Andersen S, Tarnow L, Cambien F et al.: Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/ deletion genotype? Kidney Int. 62(1), 192-198 (2002).
68. Andersen S, Tarnow L, Cambien F et al.: Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26(5), 1501-1506 (2003).
69. Coto E, Marin R, Alvarez V et al.: [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. Nefrologia 25(4), 381-386 (2005).
70. Haneda M, Kikkawa R, Sakai H, Kawamori R: Antiproteinuric effect of candesartan cilexetil in Japanese subjects with Type 2 diabetes and nephropathy. Diabetes Res. Clin. Pract. 66(1), 87-95 (2004).
71. Park HC, Choi H Y, Kim BS et al.: Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism. Kidney Blood Press. Res. 29(4), 216-224 (2006).
72. Parving HH, de Zeeuw D, Cooper ME et al.: ACE gene polymorphism and losartan treatment in Type 2 diabetic patients with nephropathy. J. Am. Soc. Nephrol. 19(4), 771-779 (2008).
73. Redon J, Luque-Otero M, Martell N, Chaves FJ: Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J. 5(1), 14-20 (2005).
74. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J. Hypertens. 14(2), 259-262 (1996).
75. O'Toole L, Stewart M, Padfield P, Charmer K: Effect of the insertion/ deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J. Cardiovasc. Pharmacol. 32(6), 988-994 (1998).
76. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E: Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 62(5), 1718-1723 (2002).
77. Kohno M, Yokokawat K, Minami M et al.: Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventriculair hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am. J. Med. 106(5), 544-549 (1999).
78. Sasaki M, Oki T, Iuchi A et al.: Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J. Hypertens. 14(12), 1403-1408 (1996).
79. McNamara DM, Holubkov R, Janosko K et al.: Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103(12), 1644-1648 (2001).
80. Harrap SB, Tzourio C, Cambien F et al.: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42(3), 297-303 (2003).
81. Arnett DK, Davis BR, Ford CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111(25), 3374-3383 (2005).
82. Mochizuki S, Dahlof B, Shimizu M et al.: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369(9571), 1431-1439 (2007).
83. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 71(1), 169-180 (1992).
84. Rogus JJ, MoczuIski D, Freire MB, Yang Y, Warrain JH, Krolewski AS: Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study. Hypertension 31(2), 627-631 (1998).
85. Reyes-Engel A, Morcillo L, Aranda FJ et al.: Influence of gender and genetic variability on plasma angiotensin pepticles. J. Renin Angiotensin Aldosterone Syst. 7(2), 92-97 (2006).
86. Brand E, Chatelain N, Paillard F et al.: Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur. J. Hum. Genet. 10(11), 715-723 (2002).
87. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A: Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol. Dial. Transplant. 21(4), 979-983 (2006).
88. Fradin S, Goulet-Salmon B, Chantepie M et al.: Relationship between polymorphisms in the renin-angiotensin system and nephropathy in Type 2 diabetic patients. Diabetes Metab. 28(1), 27-32 (2002).
89. Hadjadj S, Belloum R, Bouhanick B et al.: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in Type 1 diabetes mellitus: a prospective study. J. Am. Soc. Nephrol. 12(3), 541-549 (2001).
90. Woo KT, Lau YK, Choong LH et al.: Polymorphism of renin-angiotensin system genes in IgA nephropathy. Nephrology (Carlton) 9(5), 304-309 (2004).
91. Zychma MJ, Zukowska-Szczechowska E, Lacka BI, Grzeszczak W: Angiotensinogen M235T and chymase gene CMA/B polymorphisms are not associated with nephropathy in Type II diabetes. Nephrol. Dial. Transplant. 15 (12), 1965-1970 (2000).
92. Bonnardeaux A, Davies E, Jeunemaitre X et al.: Angiotensin II Type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24(1), 63-69 (1994).
93. Buraczynska M, Ksiazek P, Lopatynski J, Spasiewicz D, Nowicka T, Ksiazek A: [Association of the renin-angiotensin system gene polymorphism with nephropathy in Type II diabetes]. Pol. Arch. Med. Wewm. 108(2), 725-730 (2002).
94. Tomino Y, Makita Y, Shike T et al.: Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nepbron 82(2), 139-144 (1999).
95. Luther Y, Bantis C, Ivens K, Fehsel K, Kolb-Bachhofen V, Heering P: Effects of the genetic polymorphisms of the renin-angiotensin system on focal segmental glomerulosderosis. Kidney Blood Press. Res. 26(5-6), 333-337 (2003).
96. Konoshita T, Miyagi K, Onoe T et al.: Effect of ACE gene polymorphism on age at renal death in polycystic kidney disease in Japan. Am. J. Kidney Dis. 37(1), 113-118 (2001).
97. Marre M, Jeunemaitre X, Gallois Y et al.: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J. Clin. Invest. 99(7), 1585-1595 (1997).
98. Bantis C, Ivens K, Kreusser W et al.: Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am. J. Nephrol. 24(2), 258-267 (2004).
99. Osawa N, Koya D, Araki S et al.: Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J. Hum. Genet. 52(2), 143-151 (2007).